Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Press
Oct 17
•
2 min read
Vancouver, British Columbia –TheNewswire –October 16, 2024–MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6),(the “Company” or “MindBio”),a leading biopharmaceutical company in psychiatric medicine development, is pleased to provide notice of proposed issuance of listed securities in the Company via private placement to raise up to CAD$200,000 based on a 20 day VWAP or CAD 2.9 cents per share. The Company will use…
Press
TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced collaborating with Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the…
Oct 17
•
5 min read
Press
NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company’s Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from…
Oct 17
•
2 min read
Press
Toronto, Ontario–(Newsfile Corp. – October 15, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a new research partnership with the University of Nottingham, UK. This collaboration focuses on evaluating Awakn’s co-lead aminoindane series…
Oct 16
•
4 min read
Press
Vancouver, British Columbia–(Newsfile Corp. – October 15, 2024) – At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company“) wishes to confirm that the Company’s management is unaware of any material changes in the Company’s operations that would account for the recent increase in market activity. About…
Oct 16
•
1 min read
Press
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group” or the “Company“) (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the “Debt Swap Agreement“) with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (“PBM” or “Psyence Biomed“), pursuant to which Psyence Biomed has agreed to issue to…
Oct 15
•
3 min read
Press
Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval from one of its clinical sites in the U.S. for part A of its Phase…
Oct 10
•
3 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.